» Articles » PMID: 34222479

Caspase-1-Inhibitor AC-YVAD-CMK Inhibits Pyroptosis and Ameliorates Acute Kidney Injury in a Model of Sepsis

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2021 Jul 5
PMID 34222479
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To observe the protective effect of AC-YVAD-CMK on sepsis-induced acute kidney injury in mice and to explore its possible mechanisms primarily.

Methods: Eighteen male C57BL/6 mice were randomly divided into sham-operated group (Control), cecal ligation and puncture group (CLP), and CLP model treated with AC-YVAD-CMK group (AC-YVAD-CMK) ( = 6 in each group). Mice were sacrificed at 24 h after operation, and blood and kidney tissue samples were collected for analyses. Histologic changes were determined microscopically following HE staining. The expression of Ly-6B and CD68 was investigated using immunohistochemistry. Serum concentrations of creatinine (sCR) and blood urea nitrogen (BUN) were measured. Serum levels of interleukin-1 (IL-1), interleukin-18 (IL-18), TNF-, and interleukin-6 (IL-6) were determined by ELISA. The expressions of Caspas-1, NLRP-1, IL-1, and IL-18 in renal tissues were investigated using Western blot. Immunofluorescence staining was used to detect the expression of GSDMD protein in renal tissues.

Results: AC-YVAD-CMK treatment significantly alleviates sepsis-induced acute kidney injury, with decreased histological injury in renal tissues, suppresses the accumulation of neutrophils and macrophages in renal tissues, and decreased sCR and BUN level ( < 0.05). Attenuation of sepsis-induced acute kidney injury was due to the prohibited production of inflammatory cytokines and decrease expression of Caspas-1, NLRP-1, IL-1, and IL-18 in renal tissues. In addition, AC-YVAD-CMK treatment significantly reduced the expression of GSDMD in renal tissues compared to those observed in controls ( < 0.05).

Conclusions: We demonstrated a marked renoprotective effect of caspase-1-inhibitor AC-YVAD-CMK in a rat model of sepsis by inhibition of pyroptosis.

Citing Articles

Inflammasomes and idiopathic inflammatory myopathies.

Sun R, Chu J, Li P Front Immunol. 2024; 15:1449969.

PMID: 39723212 PMC: 11668653. DOI: 10.3389/fimmu.2024.1449969.


Immunoadjuvant therapy in the regulation of cell death in sepsis: recent advances and future directions.

Islam M, Watanabe E, Salma U, Ozaki M, Irahara T, Tanabe S Front Immunol. 2024; 15:1493214.

PMID: 39720718 PMC: 11666431. DOI: 10.3389/fimmu.2024.1493214.


IL-18 biology in severe asthma.

Thawanaphong S, Nair A, Volfson E, Nair P, Mukherjee M Front Med (Lausanne). 2024; 11:1486780.

PMID: 39554494 PMC: 11566457. DOI: 10.3389/fmed.2024.1486780.


Beyond Inflammation: Role of Pyroptosis Pathway Activation by Gram-Negative Bacteria and Their Outer Membrane Vesicles (OMVs) in the Interaction with the Host Cell.

Resta S, Guerra F, Tala A, Bucci C, Alifano P Cells. 2024; 13(21.

PMID: 39513865 PMC: 11545737. DOI: 10.3390/cells13211758.


Taking AIM at Influenza: The Role of the AIM2 Inflammasome.

Xu D, Tate M Viruses. 2024; 16(10).

PMID: 39459869 PMC: 11512208. DOI: 10.3390/v16101535.


References
1.
Silverman W, de Rivero Vaccari J, Locovei S, Qiu F, Carlsson S, Scemes E . The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J Biol Chem. 2009; 284(27):18143-51. PMC: 2709345. DOI: 10.1074/jbc.M109.004804. View

2.
Schroder K, Tschopp J . The inflammasomes. Cell. 2010; 140(6):821-32. DOI: 10.1016/j.cell.2010.01.040. View

3.
Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z . Regulated cell death in AKI. J Am Soc Nephrol. 2014; 25(12):2689-701. PMC: 4243360. DOI: 10.1681/ASN.2014030262. View

4.
Wu D, Pan P, Liu B, Su X, Zhang L, Tan H . Inhibition of Alveolar Macrophage Pyroptosis Reduces Lipopolysaccharide-induced Acute Lung Injury in Mice. Chin Med J (Engl). 2015; 128(19):2638-45. PMC: 4736856. DOI: 10.4103/0366-6999.166039. View

5.
Shao B, Xu Z, Han B, Su D, Liu C . NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015; 6:262. PMC: 4633676. DOI: 10.3389/fphar.2015.00262. View